-
Je něco špatně v tomto záznamu ?
Synthesis and Evaluation of Asymmetric Acyclic Nucleoside Bisphosphonates as Inhibitors of Plasmodium falciparum and Human Hypoxanthine-Guanine-(Xanthine) Phosphoribosyltransferase
P. Špaček, DT. Keough, M. Chavchich, M. Dračínský, Z. Janeba, L. Naesens, MD. Edstein, LW. Guddat, D. Hocková,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- antimalarika chemie farmakologie MeSH
- bisfosfonáty chemie farmakologie MeSH
- lidé MeSH
- nukleosidy chemie farmakologie MeSH
- pentosyltransferasy antagonisté a inhibitory metabolismus MeSH
- Plasmodium falciparum účinky léků enzymologie metabolismus MeSH
- simulace molekulového dockingu MeSH
- tropická malárie farmakoterapie enzymologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Acyclic nucleoside bisphosphonates (ANbPs) have previously been shown to be good inhibitors of human hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and Plasmodium falciparum (Pf) hypoxanthine-guanine-xanthine phosphoribosyltransferase (PfHGXPRT). On the basis of this scaffold, a new series of ANbPs was synthesized. One of these new ANbPs, [3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid, exhibited Ki values of 6 and 70 nM for human HGPRT and Pf HGXPRT, respectively. These low Ki values were achieved by inserting an extra carbon atom in the linker connecting the N(9) atom of guanine to one of the phosphonate groups. The crystal structure of this ANbP in complex with human HGPRT was determined at 2.0 Å resolution and shows that it fills three key pockets in the active site. The most potent phosphoramidate prodrugs of these compounds have IC50 values in the low micromolar range in Pf lines and low toxicity in human A549 cells, demonstrating that these ANbPs are excellent antimalarial drug leads.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17030648
- 003
- CZ-PrNML
- 005
- 20171026120547.0
- 007
- ta
- 008
- 171025s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.7b00926 $2 doi
- 035 __
- $a (PubMed)28813147
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Špaček, Petr $u The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences , Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic.
- 245 10
- $a Synthesis and Evaluation of Asymmetric Acyclic Nucleoside Bisphosphonates as Inhibitors of Plasmodium falciparum and Human Hypoxanthine-Guanine-(Xanthine) Phosphoribosyltransferase / $c P. Špaček, DT. Keough, M. Chavchich, M. Dračínský, Z. Janeba, L. Naesens, MD. Edstein, LW. Guddat, D. Hocková,
- 520 9_
- $a Acyclic nucleoside bisphosphonates (ANbPs) have previously been shown to be good inhibitors of human hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and Plasmodium falciparum (Pf) hypoxanthine-guanine-xanthine phosphoribosyltransferase (PfHGXPRT). On the basis of this scaffold, a new series of ANbPs was synthesized. One of these new ANbPs, [3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid, exhibited Ki values of 6 and 70 nM for human HGPRT and Pf HGXPRT, respectively. These low Ki values were achieved by inserting an extra carbon atom in the linker connecting the N(9) atom of guanine to one of the phosphonate groups. The crystal structure of this ANbP in complex with human HGPRT was determined at 2.0 Å resolution and shows that it fills three key pockets in the active site. The most potent phosphoramidate prodrugs of these compounds have IC50 values in the low micromolar range in Pf lines and low toxicity in human A549 cells, demonstrating that these ANbPs are excellent antimalarial drug leads.
- 650 _2
- $a antimalarika $x chemie $x farmakologie $7 D000962
- 650 _2
- $a bisfosfonáty $x chemie $x farmakologie $7 D004164
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a tropická malárie $x farmakoterapie $x enzymologie $7 D016778
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a nukleosidy $x chemie $x farmakologie $7 D009705
- 650 _2
- $a pentosyltransferasy $x antagonisté a inhibitory $x metabolismus $7 D010430
- 650 _2
- $a Plasmodium falciparum $x účinky léků $x enzymologie $x metabolismus $7 D010963
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Keough, Dianne T $u School of Chemistry and Molecular Biosciences, The University of Queensland , Brisbane, Queensland 4068, Australia.
- 700 1_
- $a Chavchich, Marina $u Department of Drug Evaluation, Australian Army Malaria Institute , Enoggera, Brisbane, Queensland 4051, Australia.
- 700 1_
- $a Dračínský, Martin $u The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences , Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic.
- 700 1_
- $a Janeba, Zlatko $u The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences , Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic.
- 700 1_
- $a Naesens, Lieve $u Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research-KU Leuven , Herestraat 49, B-3000 Leuven, Belgium.
- 700 1_
- $a Edstein, Michael D $u Department of Drug Evaluation, Australian Army Malaria Institute , Enoggera, Brisbane, Queensland 4051, Australia.
- 700 1_
- $a Guddat, Luke W $u School of Chemistry and Molecular Biosciences, The University of Queensland , Brisbane, Queensland 4068, Australia.
- 700 1_
- $a Hocková, Dana $u The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences , Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic.
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 60, č. 17 (2017), s. 7539-7554
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28813147 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171026120631 $b ABA008
- 999 __
- $a ok $b bmc $g 1254241 $s 991675
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 60 $c 17 $d 7539-7554 $e 20170830 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20171025